Skip to main content
. 2011 Sep 8;13(12):1308–1323. doi: 10.1093/neuonc/nor134

Fig. 4.

Fig. 4.

Thymus-derived Tregs predominate and proliferate in the RasB8 transgenic mouse brain tumor model. (A) Representative flow cytometry demonstrating the side scatter (SSC) and CD4 marker gating strategy in the brain, spleen, thymus, and draining lymph nodes (dLNs). (B) Representative flow cytometry demonstrating the gating strategy for determining CD4+FoxP3+ T cells (gated on CD4+ T cells) in the brain, spleen, thymus, and dLN. Quantification of the data from flow cytometry is shown in the bar graphs for brain (white bar), spleen (grey bar), thymus (black bar), and dLN (hatched bar) (n= 3 per group). (C) Representative flow cytometry demonstrating the gating strategy for determining CD4+FoxP3+Helios+ T cells (gated on CD4+FoxP3+ T cells) in the brain, spleen, thymus, and dLN. Quantification of the data from flow cytometry is shown in the bar graphs for brain (white bar), spleen (grey bar), thymus (black bar), and dLN (hatched bar) (n= 3 per group). (D) Representative flow cytometry for the level of Helios+ (thymus-derived) Tregs, Helios− (tumor-induced) Tregs, and CD4+ conventional T cells that express the proliferation marker Ki67 (n= 3 per group). Data in B–D are shown as mean ± SEM and are representative of 3 independent experiments. *P< .05, **P< .01, ***P< .001.